Expanded Access to Veliparib
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03123211|
Expanded Access Status : No longer available
First Posted : April 21, 2017
Last Update Posted : May 24, 2022
- Study Details
- Tabular View
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound Triple Negative Breast Cancer (TNBC) High Grade Serous Ovarian Cancer Patients Requiring Veliparib Suspension Formulation||Drug: Veliparib|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients, Intermediate-size Population|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||Expanded Access to Veliparib|
- Drug: Veliparib
Veliparib will be administered orally.Other Name: ABT-888
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- The patient has relapsed/refractory disease and exhausted all standard treatments.
- The patient has documented Breast Cancer (BRCA), BRCA associated RING domain (BARD), or Partner and Localizer of Breast Cancer (PALB) or other acceptable deoxyribonucleic acid (DNA) mutations.
- The patient is eligible for a Poly Adenosine diphosphate ribose polymerase (PARP) inhibitor clinical trial.
- The patient has previously received a PARP inhibitor for the same disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03123211
|Study Director:||ABBVIE INC.||AbbVie|
|Other Study ID Numbers:||
C19-918 ( Other Grant/Funding Number: AbbVie )
C20-120 ( Other Grant/Funding Number: AbbVie )
|First Posted:||April 21, 2017 Key Record Dates|
|Last Update Posted:||May 24, 2022|
|Last Verified:||May 2022|
Special Access Program
Named Patient Basis
Special Access Scheme
Triple Negative Breast Neoplasms
Neoplasms by Site
Poly(ADP-ribose) Polymerase Inhibitors
Molecular Mechanisms of Pharmacological Action